Joana Goncalves Sells 7,000 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the company’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $31.81, for a total transaction of $222,670.00. Following the completion of the transaction, the insider owned 1,518 shares of the company’s stock, valued at $48,287.58. This trade represents a 82.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Joana Goncalves also recently made the following trade(s):

• On Friday, December 19th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $30.61, for a total transaction of $214,270.00.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $33.40 on Friday. The firm has a 50-day moving average of $29.60 and a two-hundred day moving average of $22.11. The stock has a market cap of $1.62 billion, a P/E ratio of -17.58 and a beta of -0.39. Oruka Therapeutics, Inc. has a 1-year low of $5.49 and a 1-year high of $33.85.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Wednesday, November 12th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.01. As a group, equities analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors have recently bought and sold shares of ORKA. Financial Enhancement Group LLC bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $631,000. B Group Inc. raised its holdings in Oruka Therapeutics by 28.8% during the second quarter. B Group Inc. now owns 75,000 shares of the company’s stock worth $841,000 after purchasing an additional 16,785 shares in the last quarter. Geode Capital Management LLC lifted its position in Oruka Therapeutics by 100.6% in the second quarter. Geode Capital Management LLC now owns 707,406 shares of the company’s stock worth $7,932,000 after purchasing an additional 354,821 shares during the period. Affinity Asset Advisors LLC boosted its stake in Oruka Therapeutics by 10.7% during the 2nd quarter. Affinity Asset Advisors LLC now owns 603,479 shares of the company’s stock valued at $6,765,000 after purchasing an additional 58,117 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Oruka Therapeutics by 40.6% during the 2nd quarter. Franklin Resources Inc. now owns 1,012,968 shares of the company’s stock valued at $11,355,000 after purchasing an additional 292,421 shares in the last quarter. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analysts Forecast Growth

ORKA has been the topic of a number of research analyst reports. Barclays initiated coverage on shares of Oruka Therapeutics in a research note on Monday, October 13th. They set an “overweight” rating and a $48.00 price objective on the stock. Wedbush increased their price target on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Jefferies Financial Group began coverage on Oruka Therapeutics in a report on Thursday, November 13th. They set a “buy” rating and a $45.00 target price on the stock. Finally, HC Wainwright decreased their target price on Oruka Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Oruka Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $50.67.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.